Search

everythinglearnresearchcommunity

for

Search:↓

PRP treatment increased hair density, especially in men and younger patients with AGA.

The ethanol patch test reliably identifies ALDH phenotype.

Ayurvedic treatment improved hair condition and density safely in a woman with hair loss.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.

Androgenic alopecia significantly affects adults' quality of life, especially in men and employed individuals.

Low-level laser therapy helps male and female hair loss alone or with other treatments.

Androgenic alopecia affects men's quality of life more than women's.

The laser therapy device effectively increased hair growth in people with androgenetic alopecia.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Patients were very satisfied with the multidisciplinary group visit for alopecia areata.

Researchers found four natural compounds that can change DHT levels in prostate cancer cells.

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

AI can help track and improve hair loss treatment outcomes.

A teenager's hair loss was caused by the drug quetiapine but improved after stopping the medication.

CT60 polymorphism might increase the risk of Alopecia Areata.

Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.

Alopecia areata is common in young males and linked to stress.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Two brothers from Bangladesh were diagnosed with X-linked adrenoleukodystrophy, showing neurological and adrenal symptoms.

New grading scale accurately measures hair loss severity and treatment effectiveness.

Gene variations may increase oxidative stress in male pattern baldness.

Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

A new treatment for hair loss shows promise with fewer side effects.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.